Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology.

Autor: Figiel S; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Bates A; Department of Urology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Braun DA; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Eapen R; Department of Genitourinary Oncology & Division of Cancer Surgery, Peter MacCallum Cancer Centre, The University of Melbourne, Victoria, Australia., Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg & Bavarian Cancer Research Center (BZKF), Erlangen, Germany., Manley BJ; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Milowsky MI; Department of Medicine, University of North Carolina, Chapel Hill, NC, USA., Mitchell TJ; Early Detection Centre, University of Cambridge, Cambridge, UK., Bryant RJ; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Department of Urology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Sfakianos JP; Department of Urology, Ichan School of Medicine at the Mount Sinai Hospital, New York, NY, USA., Lamb AD; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Department of Urology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: alastair.lamb@nds.ox.ac.uk.
Jazyk: angličtina
Zdroj: European urology [Eur Urol] 2025 Jan; Vol. 87 (1), pp. 8-14. Date of Electronic Publication: 2024 Sep 02.
DOI: 10.1016/j.eururo.2024.08.025
Abstrakt: New spatial molecular technologies are poised to transform our understanding and treatment of urological cancers. By mapping the spatial molecular architecture of tumours, these platforms uncover the complex heterogeneity within and around individual malignancies, offering novel insights into disease development, progression, diagnosis, and treatment. They enable tracking of clonal phylogenetics in situ and immune-cell interactions in the tumour microenvironment. A whole transcriptome/genome/proteome-level spatial analysis is hypothesis generating, particularly in the areas of risk stratification and precision medicine. Current challenges include reagent costs, harmonisation of protocols, and computational demands. Nonetheless, the evolving landscape of the technology and evolving machine learning applications have the potential to overcome these barriers, pushing towards a future of personalised cancer therapy, leveraging detailed spatial cellular and molecular data. PATIENT SUMMARY: Tumours are complex and contain many different components. Although we have been able to observe some of these differences visually under the microscope, until recently, we have not been able to observe the genetic changes that underpin cancer development. Scientists are now able to explore molecular/genetic differences using approaches such as "spatial transcriptomics" and "spatial proteomics", which allow them to see genetic and cellular variation across a region of normal and cancerous tissue without destroying the tissue architecture. Currently, these technologies are limited by high associated costs, and a need for powerful and complex computational analysis workflows. Future advancements and results through these new technologies may assist patients and their doctors as they make decisions about treating their cancer.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: